Production (Stage)
Cellectar Biosciences, Inc.
CLRB
$0.3822
-$0.031-7.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -54.50% | -16.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -49.78% | -4.37% | |||
| Operating Income | 49.78% | 4.37% | |||
| Income Before Tax | -188.46% | 84.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -180.38% | 83.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -180.38% | 83.94% | |||
| EBIT | 49.78% | 4.37% | |||
| EBITDA | 49.95% | 4.40% | |||
| EPS Basic | -154.98% | 84.92% | |||
| Normalized Basic EPS | -162.76% | 85.36% | |||
| EPS Diluted | -154.98% | 86.10% | |||
| Normalized Diluted EPS | -162.76% | 85.19% | |||
| Average Basic Shares Outstanding | 9.87% | 6.62% | |||
| Average Diluted Shares Outstanding | 9.87% | 5.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||